Personalized Treatment Strategies in the Management of Metastatic Colorectal Cancer (mCRC)

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2018 to August 1, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Bayer Healthcare and Merck & Co.

Description:
Colorectal cancer is the development of cancer from the colon or rectum (parts of the large intestine) and is the third most common cancer diagnosed in both men and women in the United States. Colorectal cancer, when discovered early, is highly treatable however, when the disease has metastasized, treatment and management become much more difficult. Metastatic colorectal cancer (mCRC) carries a poor prognosis, with a 5-year survival rate of approximately 70% for regional metastases and 13% for distant metastases. The prognosis of patients with mCRC has significantly improved in recent years with the introduction of inhibitors of the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways. Patients with stage one cancer typically have surgery as the main or first treatment while those with mCRC are treated with chemotherapy and/or targeted therapies, both alone and in combination.

Upon completion of this activity, participants will be able to:

  • Examine efficacy and safety profiles of VEGF- and EGFR-targeted agents in the treatment of metastatic colorectal cancer (mCRC)

  • Analyze the relative benefits and limitations of current targeted therapy for mCRC beyond second-line therapy

  • Describe the role of molecular biomarkers in selecting appropriate targeted agents for patients with mCRC in the clinical setting, as well as the roles of additional patient-driven factors, such as age, gender, and HRQOL

  • Integrate clinical data and guideline recommendations into personalized decisions about the optimal use of targeted therapy in treatment protocols for patients with mCRC

  • Discuss the evolving role of immunotherapy in MSI-high mCRC

  • Define the risks and adverse events associated with the VEGF- and EGFR-targeted agents indicated for the treatment of patients with mCRC in order to maximize tolerability and adherence to therapeutic regimens
     

Faculty: Richard Kim, MD
Medical Oncologist, Gastrointestinal Oncology Department
Moffitt Cancer Center
Assistant Professor of Oncology
University of South Florida, College of Medicine

Disclosure:

Dr. Kim serves on an advisory board for Bayer, Bristol-Myers Squibb and Lilly. He serves as a consultant for Bayer and Bristol-Myers Squibb. He has received grant support from Bayer, Bristol-Myers Squibb and Eisai. He serves on the speaker's bureau for Lilly and Taiho. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Bayer Healthcare and Merck & Co.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue